TITLE

Hepatitis B Vaccine: More Dangerous than the Disease

PUB. DATE
May 1999
SOURCE
Mothering;May/Jun99, Issue 94, p34
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the adverse effects of the hepatitis B vaccine according to study findings released by the National Vaccine Information Center. Statistics of serious cases of side effects reported in 1996; Need for further research on the issue according to the center.
ACCESSION #
2454613

 

Related Articles

  • Immunogenicity and Safety of a Fully Liquid DTaP-IPV-Hep B-PRP-T Vaccine at 2-4-6 Months of Age in Peru. Lanata, Claudio; Zambrano, Betzana; Ecker, Lucie; Amemiya, Isabel; Ana Gil; Santos Lima, Eduardo // Journal of Vaccines & Vaccination;2012, Vol. 3 Issue 1, p1 

    Objectives: To assess the immunogenicity and safety of a new candidate, fully liquid, hexavalent DTaP-IPVHep B-PRP-T vaccine (Hexaxim™, an AcXim family vaccine) compared to a licensed hexavalent DTaP-IPV-Hep B// PRP-T vaccine (Infanrix hexa®) in Peru. Methods: Infants born to HBsAg...

  • In vivo study of hepatitis B vaccine effects on inflammation and metabolism gene expression. Hamza, Heyam; Cao, Jianhua; Li, Xinyun; Zhao, Shuhong // Molecular Biology Reports;Mar2012, Vol. 39 Issue 3, p3225 

    Pharmaceutical companies usually perform safety testing of vaccines, but all requirements of the World Health Organization and drug pharmacopoeias depend on general toxicity testing, and the gene expression study of hepatitis B vaccine is not done routinely to test vaccine quality. In this...

  • Cobertura vacunal en niños de 12 a 47 meses de edad en estratos 1 y 2 de la zona urbana de Cali, año 2002. Rojas, Jorge H.; Zapata, Helmer; Alzate, Alberto; Rodríguez, Álvsro // Colombia Medica;ene-mar2008, Vol. 39 Issue 1, p66 

    Objective: To estimate prevalence of complete vaccination sketch in children of ages of 12 to 47 months old in strata 1 and 2 into urbane zone of Cali in the year of 2002 according to biologics and the categories of socio-demographic variables of the family, the mother and child. Methods: The...

  • No Surprise: FDA Rejects Dynavax Hepatitis B Vaccine. Shaffer, Catherine // BioWorld Today;2/26/2013, Vol. 24 Issue 37, p1 

    The article reports on the disapproval of Berkeley, California-based Dynavax Technologies Corp.'s Heplisav hepatitis B vaccine by the U.S. Food and Drug Administration (FDA). The FDA says that the product needs further evaluation for safety in the board 18 to 70 age group, and it requested...

  • Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. O'Neill, S. G.; Isenberg, D. A. // Lupus;2006, Vol. 15 Issue 11, p778 

    Concerns regarding the safety and efficacy of immunization in patients with SLE have persisted for over 60 years, despite the increased risk of infection in these patients. There are many anecdotal case reports of SLE induction or exacerbation following immunization, but overall, these events...

  • Understanding correlates of hepatitis B virus vaccination in men who have sex with men: what have we learned? Yee, L.J.; Rhodes, S.D. // Sexually Transmitted Infections;Oct2002, Vol. 78 Issue 5, p374 

    Objectives: Hepatitis B infection (HBV) is prevalent among men who have sex with men (MSM) and may lead to significant morbidity and death. Although an effective vaccine exists vaccination rates among MSM are Iow. We conducted a systematic review to synthesise the various findings from empirical...

  • Recombinant Hepatitis B Vaccine: A Review of its Immunogenicity and Protective Efficacy Against Hepatitis B. Adkins, J.C.; Wagstaff, A.J. // BioDrugs;1998, Vol. 10 Issue 2, p137 

    Recombinant hepatitis B vaccine Engerix B [Hep-B(Eng)] is a noninfectious subunit hepatitis B viral vaccine indicated for the active immunisation of adults, children and infants against hepatitis B virus infection. It contains hepatitis B surface antigen (HBsAg) which is produced by the yeast...

  • Hepatitis B Vaccine.  // Annals of Internal Medicine;Jan84, Vol. 100 Issue 1, p149 

    Announces the availability of a licensed vaccine for the prevention of hepatitis B virus infection in the U.S. Annual incidence; Duration of protective antibody levels; Response of immunosuppressed patients to vaccine.

  • Many High-risk Americans Don't Get Hepatitis B Vaccine.  // Bioscience Technology;Feb2012, Vol. 36 Issue 2, p11 

    The article reports that missed opportunities to administer the hepatitis B vaccine continue to be a reason why thousands of Americans contract the virus for the infectious liver disease annually, according to a study by Brown University researchers published in the journal "Infection."

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics